Sign inJoin waitlistJoin the waitlist

CK

Charles Kunos

Medical Director of Markey’s CRO – Department of Radiation Medicine · University of Kentucky College of Medicine

Credentials: · · · · ·

History

Markey’s CRO – Department of Radiation Medicine · University of Kentucky College of Medicine
Present

Radiation Oncology
2002–2006
Preliminary or Transitional Year
2001–2002
Case Western Reserve University School of Medicine
1997–2001

Research

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
The Lancet · 2021 · 177 citations
Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer
International journal of radiation oncology · 2014 · 156 citations
Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial
Obstetrics and Gynecology · 2009 · First of 5 authors · 129 citations

Steven Waggoner
12 papers
Robert DeBernardo
11 papers
TK
Timothy Kinsella
11 papers
Aman Chauhan
8 papers
Denise Fabian
8 papers
Fadi Abdul-Karim
7 papers
Simon Lo
7 papers
Kristine Zanotti
6 papers
Rachel Miller
6 papers
Gina Kuehn
5 papers
Kathleen Moore
5 papers · 2 as a fellow
David Gaffney
4 papers

Clinical trials

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
Principal investigator · Completed
Charles Kunos
2021–2023
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2021–2023
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Principal investigator · Completed · Phase 1
Galera Therapeutics, Inc.
2013–2016
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2011–2016